Tenax Therapeutics, Inc. (TENX) stock
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.42−0.06 (-4.05%)
Close on Nov 17, 2026Market cap $53.14MP/E –Yield –
Tenax Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Tenax Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $45.26M, up 132.0% year over year. For fiscal 2025 it was $32.67M, up 157.1% from the year before. Over ten years it grew 27.0% a year on average. The highest annual figure on record is $32.67M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.67M | +157.1% |
| FY2024 | Dec 31, 2024 | $12.71M | +293.6% |
| FY2023 | Dec 31, 2023 | $3.23M | -40.0% |
| FY2022 | Dec 31, 2022 | $5.38M | -78.6% |
| FY2021 | Dec 31, 2021 | $25.15M | +451.4% |
| FY2020 | Dec 31, 2020 | $4.56M | +31.4% |
| FY2019 | Dec 31, 2019 | $3.47M | +180.1% |
| FY2018 | Dec 31, 2018 | $1.24M | -64.9% |
| FY2017 | Dec 31, 2017 | $3.53M | -47.0% |
| FY2015 | Apr 30, 2015 | $6.66M | +122.3% |
| FY2014 | Apr 30, 2014 | $3.00M | +22.0% |
| FY2013 | Apr 30, 2013 | $2.46M | -0.3% |
| FY2012 | Apr 30, 2012 | $2.46M | -8.2% |
| FY2011 | Apr 30, 2011 | $2.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $12.85M | +109.9% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $11.54M | +103.0% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $10.54M | +129.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $10.33M | +231.9% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $6.12M | +163.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $5.68M | +112.4% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $4.59M | +170.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $3.11M | +192.0% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $2.33M | +1075.8% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $2.68M | +907.0% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.70M | +49.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $1.07M | -30.8% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $197.90K | -87.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $265.74K | -77.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $1.13M | +23.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $1.54M | +32.5% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $1.52M | +119.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $1.18M | -94.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $915.60K | +2.8% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $1.16M | +10.4% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $693.22K | -45.6% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $22.38M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $890.96K | -83.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $1.05M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $1.27M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$1.34M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $5.52M | +180.0% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$916.98K | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$649.25K | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$482.77K | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $1.97M | -72.1% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$362.63K | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$311.15K | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$58.59K | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $7.06M | +269.4% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$253.97K | -120.7% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$1.22M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$2.05M | – |
| Q4 FY2015CQ1 2015 | Apr 30, 2015 | $1.91M | – |
| Q3 FY2015CQ4 2014 | Jan 31, 2015 | $1.23M | – |
See a number that looks wrong?